SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Kimmel who wrote (187)6/29/2007 8:32:54 AM
From: Keith FeralRead Replies (1) of 418
 
Leucovorin is the most widely used drug in chemotherapy today, as the primary first line agent to stop the replication of cancer cells by binding 5FU to the enzymes receptors on the cancer cells. Morever, leucovorin also reduces the toxicity of the chemo regimen by supplying intravenous folate to the healthy cells. Cofactor crushes leucovorin's delivery of folate by directly supplying the intravenous folate to both the cancer cells and the healthy cells, increasing the response rate and reducing the toxicity. Leucovorin has to be metabolically converted to folate at the intracellular level. It's a very straightforward improvement in the drug delivery of folate.

I've already built my position over the past 2 years, no need for anymore. I don't exect a 40 bagger like Qualcomm back in the days, but it would be nice to see the company with a $1 or $2 billion valuation by the end of the year. That should take care of the stock price.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News